Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future

Authors: Férir, Geoffrey; Kaptein, Suzanne; Neyts, Johan; De Clercq, Erik

Source: Reviews in Medical Virology, Volume 18, Number 1, January 2008 , pp. 19-34(16)

Publisher: John Wiley & Sons, Ltd.

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

A decade ago, standard therapy against chronic hepatitis B virus infections only consisted of lamivudine or IFN-α. Treatment with lamivudine and IFN has been compounded by, respectively, the emergence of drug-resistant virus strains and the appearance of serious side effects. In the last 10 years, hepatitis B treatment has made much progress. Several treatments are now licensed for the treatment of patients with chronic hepatitis B and others are under development. Here, we provide an overview of the potential and mode of action of anti-HBV agents that are currently available, and/or may become available in the near future. Foremost among these newer compounds are adefovir dipivoxil, entecavir and telbivudine. Copyright © 2007 John Wiley & Sons, Ltd.

Document Type: Review article

DOI: 10.1002/rmv.554

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A